The Wegovy Starter Dose and What It's Actually For

Why 0.25mg is where Wegovy always begins

The question our prescribers hear most weeks is some version of: "Is the starting dose actually doing anything?" It's a fair thing to wonder, especially when you've read about the 2.4mg maintenance dose and the results achieved at that level in clinical trials.

The honest answer is that 0.25mg is a tolerability dose first and foremost. Semaglutide slows gastric emptying and changes appetite signalling, and those effects can produce nausea, reflux or loose stools if the dose climbs too quickly. Starting low gives your gut time to adapt. Think of it less as the first rung of a ladder and more as a settling-in period before the real climb begins.

The licensed titration schedule runs in four-week blocks: 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg as the maintenance dose, and our page on the Wegovy starting dose walks through what each of those steps involves and what you can expect along the way. Your prescriber manages the pace, it is not something to accelerate independently. The NHS semaglutide medicines page has a clear summary of how this schedule works and what to expect at each stage.

If you are curious whether it is possible to begin at a higher level, the short answer under standard prescribing is no, and there are good clinical reasons for that, which our page on starting Wegovy at a higher dose covers in detail.

What shapes your titration once you've passed 0.25mg

Moving from 0.25mg towards maintenance is not automatic. A prescriber reviews your progress before each dose increase, looking at how well the current dose is tolerated and whether there are any clinical reasons to pause the schedule. This is why clinical oversight across the full titration period matters, not just at the point of first prescription.

Side effects during titration are common and usually mild to moderate. Nausea and loose stools are the most frequently reported, and they tend to cluster in the first few days after a dose step rather than persisting throughout the four-week block. Eating smaller portions, avoiding fatty meals and staying well hydrated all help, your Patient Information Leaflet gives practical guidance tailored to the medicine. If side effects feel unmanageable, your prescriber may recommend holding at the current dose for longer rather than pushing on.

The full picture of doses, from 0.25mg through to the 2.4mg standard maintenance and the newer 7.2mg option, is covered on our Wegovy doses overview. Understanding where 0.25mg sits in that sequence helps set realistic expectations for the weeks ahead.

Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, a prescriber considers the whole clinical picture, including any medicines you already take.

The 0.25mg period and what it tells your prescriber

Those first four weeks do more than settle your stomach. They give your prescriber early information: how you're tolerating the medicine, whether you have any reactions worth monitoring, and whether there are any adjustments to consider before the dose rises. This is part of why ongoing clinical review (not just a one-off sign-off) matters throughout titration.

Some people find that appetite changes are noticeable even at 0.25mg; others feel very little difference until a higher dose. Both are normal. Our page on the start dose of Wegovy explains why the early weeks can feel slow, and that is by design. Patience at this stage reduces the likelihood of side effects becoming a reason to stop treatment altogether.

For context on how the starter dose compares to the approach used with semaglutide in other formulations, our page on the semaglutide starter dose sets that out clearly, and if you have been wondering whether starting Wegovy at 1mg is an option for you, that page explains the clinical reasoning behind why it is not standard practice. And if you are weighing Wegovy against other licensed weight-management options, the treatment overview is a good place to start.

If you are ready to find out whether Wegovy is clinically suitable for you, check your eligibility through a free consultation with our GPhC-registered prescribers, reviewed the same day, with no waiting list.